Mevion & C-RAD integrate for better treatment in proton therapy
Category: #health  By Pankaj Singh  Date: 2019-08-13
  • share
  • Twitter
  • Facebook
  • LinkedIn

Mevion & C-RAD integrate for better treatment in proton therapy
  • C-RAD to offer a specific version of Catalyst System named Catalyst PT in proton therapy.
  • Catalyst PT would be especially used for thoracic tumor indications.

Mevion Medical Systems® and C-RAD reportedly announced the combination of the MEVION S250i Proton Therapy System® & C-RAD Catalyst PT™. The combination of these substances supports a continuous workflow with uninterrupted patient monitoring and surface tracking through setup and treatment.

C-RAD provides a specific version of Catalyst System to be utilized in particle and proton therapy- Catalyst PT, based on Catalyst software and technology.

Maastro Proton Therapy, consisting of MEVION 250i Proton Therapy System along with C-RAD unveiled a strategic agreement in the previous year for installing Catalyst PT at its center. C-RAD and Mevion collaborated and developed a solution combining both of their products enabling higher level of integration to improve patient safety and user comfort.

Supported by requirements & expertise of the Maastro Proton Therapy, both the companies aimed at creation of interface needed for uninterrupted workflow, including automated patient position correction & monitoring through the complete treatment process.

Chief Executive Officer at Mevion Medical Systems, Tina Yu stated that in keeping Mevion’s commitment to offer innovative services and products, the company is proud to collaborate with C-RAD to facilitate a fully integrated and advanced proton patient positioning surface to its customers.

CEO and President of C-RAD AB, Tim Thurn stated that accurate patient monitoring during and patient positioning before the treatment is vital in radiation therapies of high precision. This development is driving interest for the company’s top-notch surface tracking solutions.

Tim Thurn added that workflow optimization and user experience is getting important for company’s customers. C-RAD’s aim has always been to set a benchmark in workflow integration and usability. This project of Mevion and C-RAD would mark a new standard for the customers.

The Catalyst PT system is available for present as well as future customers of Mevion.

 

Source Credit:

https://www.biospace.com/article/releases/mevion-and-c-rad-release-integration-for-improved-treatment-quality-in-proton-therapy/



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Flipkart launches Loyalty Program across 5,000 retail outlets in India
Flipkart launches Loyalty Program across 5,000 retail outlets in India
By Pankaj Singh

E-commerce giant Flipkart has recently launched SuperCoin Pay, a system of currency which its customers will have the right to use across tons of retail stores in the country. Flipkart is betting on its loyalty program...

Sirnaomics reveals dose administration of 1st patient in STP705 trial
Sirnaomics reveals dose administration of 1st patient in STP705 trial
By Pankaj Singh

Sirnaomics, Inc., a clinical-stage biopharmaceutical company, has recently announced the dose administration of the 1st patient in a Phase 2a clinical trial of STP705. STP705 is a lead drug candidate develop...

Pfizer’s XALKORI®) Approved by US FDA for ALK-positive ALCL treatment
Pfizer’s XALKORI®) Approved by US FDA for ALK-positive ALCL treatment
By Pankaj Singh

The pharma giant Pfizer Inc. has reportedly declared that the U.S. Food and Drug Administration (US FDA) has approved the sNDA (supplemental New Drug Application) for XALKORI® (crizotinib) for the treatment of chil...